Howson Pharmaceuticals explores the innovative way of precise diagnosis and treatment of lung cancer

Recently, "Creating Excellence in China, Miller Era-The 2nd CSCO Hausen Lung Cancer Precision Diagnosis and Treatment Forum" was held simultaneously in Shanghai, Beijing and Guangzhou
.

Academician Yu Jinming of the Chinese Academy of Engineering and Professor Wu Yilong of Guangdong Provincial People’s Hospital as the chairperson of the conference, and many participating experts focused on the exploration and innovation of lung cancer diagnosis and treatment, and once again "liked" Amelox® (ametinib mesylate), calling it The patient brings new hope of life

Only the innovators act steadily and far
.

Lv Aifeng, president of Hausen Pharmaceuticals, said in his speech that technological innovation is the key internal driving force and core competitiveness of Hausen Pharmaceuticals for its high-quality and rapid development

• 01 Science and technology provide new options for precision treatment

Amelox® is the first Chinese original third-generation EGFR-TKI innovative drug independently developed by Hausen Pharmaceuticals and the world's first third-generation EGFR-TKI with a median progression-free survival (mPFS) of more than 1 year (second-line use)
.

Since its launch for one year, Amelox® has been widely used clinically, and has won unanimous praise for its excellent clinical effects and outstanding research results

Academician Yu Jinming, the chairman of the conference, pointed out in his speech that the current research on non-small cell lung cancer has achieved many exciting results
.

Looking internationally, China's self-developed drugs, China's research, and China's data are increasingly on the world stage.

With the continuous innovation of new therapies such as targeted therapy and immunotherapy, lung cancer has gradually moved towards "chronic disease" management.
The existing clinical data fully shows that Amelox® has excellent efficacy and safety
.

Professor Lu Shun, chairman of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association, and Professor Lu Shun, director of the Department of Oncology, Shanghai Jiaotong University Thoracic Hospital, said that Amelox® can effectively improve the quality of life of patients and bring more survival gains to patients with advanced lung cancer.

On the forum, in the real cases shared by experts, it was shown that Amelox® can effectively control brain metastases and has a superior effect on brain metastases
.

It is worth mentioning that in February 2021, the Phase III study for the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer reached the main research endpoint.
Amelox® will bring the gospel to more lung cancer patients and provide more information.
Many hopes for survival, the latest research results will be released at the ASCO meeting in 2021, so stay tuned
.

• 02 Accurate "target" grip medication is safer

       As China's first original third-generation EGFR-TKI drug, Amelox® not only has significant therapeutic effects, but also has good safety
.

       In the process of targeted therapy of non-small cell lung cancer, patients often experience adverse reactions such as diarrhea and skin rash, especially interstitial pneumonia, which will seriously reduce the patient's quality of life and affect the patient's compliance with the treatment plan
.

Clinical data shows that Amelox® has a low incidence of adverse reactions, good tolerability, and high safety.

• 03 "Medical" road goes along with national innovation achievements benefiting more patients

       The value of drugs is ultimately reflected in the benefits of patients
.

In December 2020, Amelox® was included in the National Medical Insurance Catalogue.

       Recently, in order to facilitate patients, the National Medical Insurance Administration organized experts to screen the first batch of 19 drugs with urgent clinical demand and not strong substitutability from the newly negotiated drugs in 2020.

       In the future, Hausen Pharmaceuticals will integrate superior resources, focus on innovative breakthroughs in the treatment of major diseases, promote transformation and upgrading with technological innovation, continue to optimize national medicine, strengthen China's creation, and continue to meet the unending clinical medical needs for tumor diseases.